{'fraction_non_alphanumeric': 0.018685567010309278, 'fraction_numerical': 0.006443298969072165, 'mean_word_length': 5.138339920948616, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AN ELDERLY PATIENT WITH ACUTE CORONARY SYNDROME: MANAGEMENT DURING COVID-19 PANDEMIC

An increased number of elderly people in the medical terms means the pre- dominance of pathology in the morbidity structure, which is determined by comorbidity, systemic lesions and an unfavorable prognosis. Comorbid patients are the most vulnerable group with a particularly high risk of adverse outcomes. In the presented review, the problem of management of acute coronary syndro- me (ACS) in elderly patients in the context of the COVID-19 pandemic is addressed. The review demonstrates results of randomized clinical trials and registries of recent years, which purposefully included patients with ACS aged ≥ 75 years. Particular attention is paid to the need for a geriatric assessment of patients, the presence and severity of senile asthenia and its influence on the choice of treatment tactics and prognosis. The problem of choosing a method of myocardial revascularization and drug therapy schemes in elderly patients is considered under pandemic conditions. Issues related to drug interactions between drugs for the treatment of acute forms of coronary heart disease and drugs for the treatment of COVID-19 are reflected. In this situation, taking into account the risks of possible drug-drug interactions is of particular importance, which is especially challenging in elderly comorbid pa- tients. Based on the available data, we have analyzed the main trends in the choice of treatment tactics for elderly patients with ACS during the COVID-19 pandemic.